Navigation Links
AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency
Date:5/15/2008

AARP commends Governor Paterson's leadership in proposing prescription drug marketing reform and transparency

ALBANY, N.Y., May 15 /PRNewswire-USNewswire/ -- AARP strongly believes New York has a paramount interest in passing the Governor's prescription marketing reform proposals which address the undue influence that pharmaceutical companies have over prescribing decisions that affect not only consumers' pocket books but the treatment they receive.

The reforms include banning gifts of over $50 (excluding free samples) to doctors and requiring speakers at continuing medical education programs for health professionals to disclose any financial relationships they might have with a drug company.

AARP strongly supports provisions in the proposed legislation to make the business transactions of pharmaceutical benefit managers (PBMs) more transparent in order to drive down the cost of prescription drugs.

We strongly encourage the New York State Legislature to pass this legislation that would help so many New Yorkers before the end of the legislative session. The pharmaceutical industry should not dictate prescription drug policy in our State. The Legislature must reject the opposition from the drug industry and do the right thing for their constituents.

The Governor's bill will increase a New Yorker's ability to access affordable prescription drugs and improve the quality of their healthcare. In addition, this legislation would help all taxpayers who fund public prescription drug programs, such as Medicaid and EPIC.

According to a January 2006 article in the Journal of the American Medical Association (JAMA), titled "Health Industry Practices That Create Conflicts of Interest," approximately 90% of the $21 billion pharmaceutical industry marketing budget continues to be directed at physicians.

When a drug company sales representative walks into a doctor's office armed with gifts and promotes a drug company's newest,
'/>"/>

SOURCE AARP New York
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 On April 2, ... Trying to Achieve Kylie Jenner Lips With ... have injured themselves while attempting an at-home lip ... Twitter is that creating an airlock around one’s mouth ... to plump and achieve Kylie Jenner’s now famous pout. ...
(Date:4/21/2015)... Texas (PRWEB) April 22, 2015 ... Review, H1 2015” provides comparative analysis on ... report strengthens R&D pipelines by identifying new ... best-in-class products. Complete report with TOC is ... The report also reviews key players involved ...
(Date:4/21/2015)... The California Healthcare Institute (CHI), ... sciences organizations, released the following statement by CHI ... Assembly Bill (AB) 463: , “As innovators in ... of treatments and cures for patients with serious ... AB 463, the so-called Pharmaceutical Cost Transparency Act ...
(Date:4/21/2015)... Vancouver, BC (PRWEB) April 21, 2015 ... offers complimentary pick-up and delivery for clients that avail ... South Surrey by Angelo’s is done with hi-tech equipments, ... inconvenience for customers. They use all natural, high pressure ... as well as hand washing for area rugs made ...
(Date:4/21/2015)... Danvers, MA (PRWEB) April 21, 2015 ... managed mobility services, has been recognized by the Boston ... Massachusetts. The ranking was announced at a recent ... Journal’s annual list of the fastest-growing private companies in ... held businesses in the state that recorded the fastest ...
Breaking Medicine News(10 mins):Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:California Healthcare Institute Statement on AB 463 2Health News:California Healthcare Institute Statement on AB 463 3Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2
... 2 MedWaves, Inc. announces the receipt of ... is in addition to having already received U.S. ... Microwave Coagulation/Ablation System for surgical applications. The system ... interventional radiologists to treat soft tissue problems, such ...
... BEACH, Va., Feb. 2 AMERIGROUP Corporation (NYSE: ... plan in the State of Nevada began offering healthcare ... Children,s Health Insurance (SCHIP) programs beginning February 1, 2009. ... of Nevada," said James G. Carlson, AMERIGROUP Chairman and ...
... in customer and technical supportPORTLAND, Ore., Feb. 2 ... Vice President of Customer Support. With nearly 20 years ... managing customer inquiries, special service requests, and technical support ... leadership, she has also developed new programs to smooth ...
... Opportunity Partners, LLC ("Xmark"), the sole member of the investment ... Ltd., has, in the past, sent letters to the Board ... setting forth its dissatisfaction with the company,s corporate governance, management ... opportunity to respond to the Form 8-K filed by the ...
... Mich., Feb. 2 Dorothy Carpenter had stomach problems her ... or pasta could lead to terrible pain.Her illness went undiagnosed ... System physician recognized it as celiac disease. By then her ... forced doctors to remove part of her small intestine."I,ve been ...
... JOLLA, Calif., Feb. 2 Transdel Pharmaceuticals, ... ), a specialty pharmaceutical company focused on ... has retained FLP Pharma, a Georgia-based pharmaceutical ... especially the out-licensing of its lead product ...
Cached Medicine News:Health News:MedWaves, Inc. Announces Receipt of MDD CE Certification and Additional U.S. FDA 510(k) Clearance to Market Its Patented Microwave Coagulation/Ablation System and Devices 2Health News:AMERIGROUP Health Plan in Nevada Begins Serving Medicaid Enrollees 2Health News:GI Condition Once Thought Rare is Common in U.S. 2Health News:GI Condition Once Thought Rare is Common in U.S. 3Health News:Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities 2Health News:Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities 3
(Date:4/21/2015)... YORK , April 21, 2015 EpiCast ... Summary Sepsis is a life-threatening complication arising from ... the infection damages its own tissues and organs. Anyone ... among children <1 year of age, older ... 2014). Global estimates for the year 2013 showed that ...
(Date:4/21/2015)... -- Global cap & closure demand to ... and closures will exceed $55 billion in 2019. In unit ... Beverages will continue to account for well over half of ... smaller markets are expected to register faster growth. ... developed markets -- the US, Western Europe ...
(Date:4/21/2015)... 21, 2015 Gary A. Puckrein , ... Quality Forum (NMQF), today will present an award ... Pharmaceutical Research and Manufacturers of America (PhRMA), for ... On behalf of PhRMA, and in conjunction with NMQF, ... build awareness, start conversations, and increase diversity in clinical ...
Breaking Medicine Technology:EpiCast Report: Sepsis - Epidemiology Forecast to 2023 2EpiCast Report: Sepsis - Epidemiology Forecast to 2023 3World Caps & Closures Market 2World Caps & Closures Market 3National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 2National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 3
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
Rapid immunochromatographic membrane test for RSV. Accepts nasopharyngeal washes, aspirates, and swabs....
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products: